Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.

被引：0
|
作者：
Pant, Shubham
Schuler, Martin H.
Iyer, Gopa
Witt, Olaf
Doi, Toshihiko
Qin, Shukui
Tabernero, Josep
Reardon, David A.
Massard, Christophe
Welsh, Liam
Lugowska, Iwona A.
Carranza, Omar
Stuyckens, Kim
Liao, Huimin
Najmi, Saltanat
Hammond, Constance
Thomas, Shibu
Triantos, Spyros
Sweiti, Hussein
Loriot, Yohann
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Univ Heidelberg Hosp, Hopp Childrens Canc Ctr KiTZ, German Canc Res Ctr Heidelberg, Heidelberg, Germany
[5] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany
[6] Natl Canc Ctr Hosp East, Chiba, Japan
[7] Nanjing Univ Chinese Med, Jinling Hosp, Nanjing, Peoples R China
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Dana Farber Canc Inst, Boston, MA USA
[11] Univ Paris Saclay, Gustave Roussy, Villejuif, France
[12] Royal Marsden NHS Fdn Trust, London, England
[13] Narodowy Instytut Onkologii, Marii Sklodowskiej Curie Panstwowy Inst Badawczy, Warsaw, Poland
[14] Hosp Privado Comunidad Mar Plata, Mar Del Plata, Argentina
[15] Janssen Res & Dev, Beerse, PA, Belgium
[16] Janssen Res & Dev, Shanghai, Peoples R China
[17] Janssen Res & Dev, Spring House, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3121
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non emuscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
    Vilaseca, A.
    Jayram, G.
    Raventos, C.
    Shore, N. D.
    Zainfeld, D.
    Kang, T. W.
    Ku, J. H.
    Meeks, J.
    Faba, O. Rodriguez
    Roghmann, F.
    Daneshmand, S.
    Beeharry, N.
    Cost, C.
    Kalota, A.
    Lauring, J.
    Peterson, M.
    Quiroz, M.
    Stone, N.
    Zhu, W.
    Guerrero-Ramos, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S1343 - S1343
  • [22] Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
    Siefker-Radtke, A. O.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Ozguroglu, M.
    Perez Valderrama, B.
    Triantos, S.
    Akapame, S.
    Kean, Y.
    Deprince, K.
    Mukhopadhyay, S.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1199 - S1199
  • [23] Identifying potential mechanisms of resistance to erdafitinib (erda) via longitudinal analysis of circulating tumor (ct)-DNA of patients (pts) with advanced/metastatic urothelial cancer
    Guercio, Brendan J.
    Sarfaty, Michal
    Teo, Min Yuen
    Funt, Samuel A.
    Lee, Chung-Han
    Aggen, David H.
    Ratna, Neha
    Regazzi, Ashley M.
    Chen, Ziyu
    Lattanzi, Michael
    Al-Ahmadie, Hikmat A.
    Brannon, A. Rose
    Berger, Michael F.
    Solit, David B.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Iyer, Gopa
    CANCER RESEARCH, 2022, 82 (12)
  • [24] Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
    Park, Joon Oh
    Feng, Yin-Hsun
    Chen, Yen-Yang
    Su, Wu-Chou
    Oh, Do-Youn
    Shen, Lin
    Kim, Kyu-Pyo
    Liu, Xiufeng
    Bai, Yuxian
    Liao, Huimin
    Nie, Jing
    Qing, Min
    Ji, Qinmei
    Li, Jiongyan
    Zhao, Mianzhi
    De Porre, Peter
    Monga, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure–QTc in patients with advanced or refractory solid tumors
    Elodie Valade
    Anne-Gaëlle Dosne
    Hong Xie
    Robert Kleiman
    Lilian Y. Li
    Juan José Perez-Ruixo
    Daniele Ouellet
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 621 - 633
  • [26] Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
    Siefker-Radtke, A. O.
    Loriot, Y.
    Siena, S.
    Beato, C.
    Climent Duran, M. A.
    Varlamov, S.
    Duran, I.
    Tagawa, S. T.
    Geoffrois, L.
    Mellado, B.
    Semenov, A.
    Delva, R.
    Lykov, A. P.
    Dirix, L. Y.
    Akapame, S.
    O'Hagan, A.
    Tammaro, M.
    Mosher, S.
    Kang, T. W.
    Moreno, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S584 - S585
  • [27] Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
    Rolfo, Christian Diego
    De Braud, Filippo G.
    Doebele, Robert Charles
    Drilon, Alexander E.
    Siena, Salvatore
    Patel, Manish
    Cho, Byoung Chul
    Liu, Stephen, V
    Myung-Ju Ahn
    Chiu, Chao-Hua
    Farago, Anna F.
    Goto, Koichi
    Lee, Jeeyun
    Bazhenova, Lyudmila
    John, Tom
    Fakih, Marwan
    Simmons, Brian P.
    Pitcher, Bethany
    Huang, Xinhui
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] A phase I clinical trial of recombinant human endostatin (rHE) in patients (PTS) with solid tumors: Pharmacokinetic (PK), safety and efficacy analysis.
    Herbst, R
    Tran, H
    Hess, K
    Madden, T
    Charnsangavej, C
    Gravel, D
    Terry, K
    Guerra, M
    Taebel, K
    Ellis, L
    Pluda, J
    Hong, WK
    Abbruzzese, J
    CLINICAL CANCER RESEARCH, 2000, 6 : 4518S - 4518S
  • [29] Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
    Nishina, Tomohiro
    Takahashi, Shunji
    Iwasawa, Ryota
    Noguchi, Hidehisa
    Aoki, Masayuki
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (03) : 424 - 434
  • [30] Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors
    Tomohiro Nishina
    Shunji Takahashi
    Ryota Iwasawa
    Hidehisa Noguchi
    Masayuki Aoki
    Toshihiko Doi
    Investigational New Drugs, 2018, 36 : 424 - 434
12345